secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001708599-25-000076
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development
-------------------------------------------------------------------------------

- SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).
- U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.
- Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.
- Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.
- CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/0001708599-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/ser-20250729.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer